Citigroup Maintains Buy on Wave Life Sciences, Lowers Price Target to $15
Citigroup analyst Samantha Semenkow maintains Wave Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $19 to $15.
Last updated: 2026-11-19 11:13:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Wave Life Sciences Ltd. (WVE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.85, with a market capitalization of $560.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.75 to $21.73. This page covers its latest market performance, valuation, price trends and company information.
$560.13M | |
$2.79 | |
$2.86 | |
$2.79 | |
$2.77 | |
1.39K | |
3.14M | |
-- | |
$21.73 | |
$2.75 | |
-- | |
2026-09-30 |
Wave Life Sciences Ltd. (WVE) is trading at $2.85 in pre-market trading as of 2026-11-19 10:51:00, up 2.96% ($0.08) from the previous close of $2.77
Pre-market trading shows how investors are pricing WVE before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Wave Life Sciences Ltd. (WVE) moved from $3.41 to $2.85, representing a decline of 16.36% ($0.56).
The stock traded between $2.75 and $3.56 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.22 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.5%
WVE is currently trading at $2.85, placing it 0.5% of the way from its 52-week low of $2.75 to its 52-week high of $21.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 317 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Wave Life Sciences Ltd. and WVE stock.
Citigroup analyst Samantha Semenkow maintains Wave Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $19 to $15.
Eligible investors can buy real shares of Wave Life Sciences Ltd. (WVE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to WVE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between WVE shares and USD.
WVE Shares to USD
1.00 WVE shares = 2.852 USD
Calculations are estimates based on the latest available price and are for reference only.